At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
Glial growth factor 2/ Neuregulin 1β3 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Double-Blind, Placebo-Controlled Study of Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure
In Brief
A Phase 1 clinical trial evaluating Glial growth factor 2/ Neuregulin 1β3 and Placebo for Heart Failure. Completed, enrolled 40 participants across 2 sites.
Detailed Summary
Study to determine the safety, tolerability, pharmacokinetics and immunogenicity of single intravenous administrations of GGF2 in patients with heart failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedDec 2010
Primary CompletionDec 2012
Study CompletionMar 2013
TodayJul 2026
First PostedDec 13, 2010
Enrollment StartDec 1, 2010
Primary CompletionDec 1, 2012
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 15.6 years ago
Interventions
Glial growth factor 2/ Neuregulin 1β3drug
Placeboother